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The decision to have an amniocentesis entails a trade-off between a risk of procedure associated miscarriage and
the benefit of obtaining diagnostic information to identify Down syndrome or other chromosomal aneuploidy.
Ideally, this trade-off is informed by first and second trimester pre-natal screening tests, such that women with low
risk screening test results are not encouraged to have an amniocentesis.
In a recent IJHPR article, Grinshpun-Cohen et al. surveyed 42 Israeli women without a medical indication for
amniocentesis other than age. They found that one third of women who had a noninvasive serum screening test
prior to amniocentesis did not even wait for the test results before electing to have the invasive procedure and
10 % of women did not have any serum screening test prior to amniocentesis.
There may be multiple reasons why women of advanced maternal age are not integrating screening risk information
into their decision-making about amniocentesis. However, our understanding of those reasons is limited, as we don’t
have information on the content of conversations between health care providers and women who are considering
amniocentesis. We don’t know if health care providers counseled women on how screening risk information can
inform their decision about whether or not to purse a diagnostic amniocentesis. Even if women with screening tests
results suggestive of a low risk of Down syndrome were counseled not to pursue an amniocentesis, some women may
have a preference for diagnostic information about a fetus’s Down syndrome status. Health care providers should,
however, be encouraged to engage women in a process of shared decision making to ensure that women are
informed and making deliberative decisions that meet their goals of care. Offering women a relatively new, cell-free
fetal DNA test may provide reassurance that negates the impulse to have an amniocentesis. Public funding for
amniocentesis for all women of advanced maternal age should continue as the decision to purse an amniocentesis is
best determined by women who have to live with the consequences of their choice.
Commentary
Background
What factors should enter into a woman’s decision to
undergo amniocentesis? Is the mere fact of advanced
maternal age sufficient to justify the risk of miscarriage
associated with the invasive diagnostic procedure? From
a public policy perspective, should public funding cover
amniocentesis for all women who are older than 37 years
of age at the onset of their pregnancy, regardless of other
risk factors? What should be the role of health care pro-
viders in helping women deliberate about the decision to
pursue an amniocentesis?
In their important study on the effect of risk informa-
tion on women’s decisions to undergo amniocentesis,
which was recently published in the Israel Journal of
Health Policy and Research, Grinshpun-Cohen et al. [1]
surveyed 42 women without a medical indication for
amniocentesis other than age. They evaluated their
knowledge and opinions regarding screening tests, risks
of amniocentesis, and factors that affected the decision
to pursue amniocentesis with an eye toward assessing if
their decisions were informed. Surprisingly, one third
of women who had a noninvasive serum screening test
prior to amniocentesis did not even wait for the test re-
sults before electing to have the invasive procedure and
10 % of women did not have any serum screening test
prior to amniocentesis. Furthermore, while most women
could recall the risk of miscarriage associated with an am-
niocentesis, many could not recall their serum screening
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test results or their age-related Down syndrome risk.
These findings suggest that women are not integrating ob-
jective risk estimates into their decision making about
whether to pursue an amniocentesis.
These findings are consistent with a recent study of
3217 women in Greece which evaluated the impact of
prenatal screening test results on the decision to undergo
amniocentesis in women older than 35. Among women
who had prenatal screening, 79 % were low risk for
Down syndrome, but nevertheless decided to have an
amniocentesis.
What might account for women’s disregard of object-
ive risk information? Does it really imply that women
are not being deliberative about the decision to have an
amniocentesis? If objective risk estimates are not fueling
women’s decisions to pursue an amniocentesis, what is?
Risk communication is very complex and may be influ-
enced by both health care providers’ and patients’ varying
perceptions of risk information. The severity and conse-
quences of the risk, as well as individual patient character-
istics and framing of risk information influence decision-
making [2, 3].
In the context of this study of women’s decision making
about amniocentesis, we don’t know how health care pro-
viders counseled women about whether and how to inte-
grate objective risk estimates into their decision making. It is
unclear if women were given tailored options about screen-
ing for Down syndrome and if the implications of different
screening approaches were explained. In a recent study by
Srebnik et al., 44 % of Israeli clinicians recommended an
amniocentesis on the basis of older age [4]. There are mul-
tiple approaches to screening and women’s preferences
should influence the approach taken [5, 6].
Ultimately, it is women’s values that should drive the
pre-natal screening process. Some women may value in-
formation about their fetus’s risk of Down syndrome
during the first trimester even if it is associated with a
higher procedure-related risk of miscarriage. For these
women a screening test that combines maternal serum
screening of beta-hCG and pregnancy-associated plasma
protein-A (PAPP-A) with ultrasound measurement of
fetal nuchal translucency will detect 85 % of Down syn-
drome fetuses at a 5 % false positive rate. Other women
may have a stronger impulse to minimize the procedure-
related pregnancy loss even if it means they won’t be
able to identify a high-risk fetus during the first trimes-
ter. For such women, an integrated test that combines
first trimester nuchal translucency, PAPP-A with second
trimester quadruple serum markers will detect 90 % of
Down syndrome fetuses and have a 1 % false positive
rate. The down side of this approach is that the results
are not available until the second trimester. Thus, women
who are open to pregnancy termination and may have a
preference for termination earlier in pregnancy will not
be in a position to make a decision about termination
until the second trimester. Still other women may place
a strong value on being absolutely certain that they are
not carrying an affected fetus. For such women, the re-
sults of a screening test won’t quell their fear and they
may be reluctant to let a screening test that returns
with a low risk of having an affected fetus dissuade
them from pursing an invasive diagnostic procedure
even if that procedure carries a risk of miscarriage.
It is generally recommended that women with screen
negative results not pursue further diagnostic testing. For
some women, however, even an excellent screening test
will not be a substitute for a definitive diagnostic test.
A negative screen only means that the risk of having a
baby with Down syndrome is less than a specified cut
off; it does not definitively dismiss the possibility of
Down syndrome.
Did the one third of women in this study who did not
await the results of their first and second trimester serum
screening tests consciously decide to accept the trade off of
possible procedure associated fetal loss for certainty that
their fetus was not affected by a chromosomal abnormality?
Were they counseled not to have an amniocentesis because
of their low risk of having an affected fetus? We simply do
not know the answer to these questions. Future research is
needed to better understand the conversations that women
have with their health care providers about pre-natal
screening and amniocentesis. A study that captures the ac-
tual conversations that women are having with their clini-
cians about prenatal screening options, the implications of
positive and negative screening tests and the role that indi-
vidual women’s values play in decision making would pro-
vide a foundation for better understanding how women are
currently being counseled and how we can improve the
process of decision making surrounding amniocentesis.
Another option for women to consider is the relatively
new screening test using a maternal plasma-based test for
cell free fetal DNA during or after the 10th week of preg-
nancy. Although it is not diagnostic, the high sensitivity
and specificity of this DNA test in both high- and low-risk
populations may reassure many women that their risk of
carrying a Down syndrome fetus is so low that it allows
them to avoid an amniocentesis [7]. Two studies support
offering cell-free DNA screening to all pregnant women
who desire screening [8, 9]. When compared with standard
screening using ultrasound nuchal translucency and mater-
nal serum markers, cell-free DNA screening of women
with a mean gestational age of 12.5 weeks (range 10–
14.3 weeks) had 100 % sensitivity for detection of Down
syndrome and a false positive rate of 0.06 % [8].
Israel has a generous policy of funding amniocentesis
for all women of who are 35 years of age or older. Al-
though pregnant women may erroneously interpret this
policy to imply that all women over 35 should have an
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amniocentesis, health care providers need tools to edu-
cate women about appropriate utilization of the test.
Given the procedure associated risks of amniocentesis it
is unlikely that informed women would opt for the pro-
cedure simply because it is funded by the government.
Health care providers have an important role to play in
helping women understand the complexity of prenatal
screening and in guiding women through a process of
shared decision making to arrive at a decision that is con-
sistent with their personal goals and values. The policy of
funding amniocentesis for all women of advanced mater-
nal age is prudent in that many women of advanced ma-
ternal age may have a strong preference for the certainty
of information associated with an amniocentesis. Contin-
ued government funding gives women and their health
care providers the freedom to make high quality tailored
clinical decisions without government interference.
A liberal public policy with regard to funding, how-
ever, comes with a significant responsibility for health
care providers. As professionals, health care providers
should be encouraged to uncover patients’ considered
goals and educate patients about their prenatal screening
options so that they can arrive at high quality deliberative
medical decisions about amniocentesis. Women should be
encouraged to undergo screening tests and incorporate
these results into their decision making about a diagnostic
amniocentesis. While it may be tempting to limit funding
for amniocentesis to women who have a high-risk screen,
such a policy is likely lead to worse outcomes for women
and their children. It is women and their families who will
have to care for a Down syndrome child and therefore it is
their goals and values, not the government’s, which should
drive clinical decision-making.
A study of patients facing surgical procedures found that
informed patients opt for less surgery than those in “usual
care” [10]. More informed patients seem to opt for less
costly conservative treatment options. Instead of develop-
ing policies that restrict government funding, we should be
creating decision aids to help women make high quality
informed decisions and encouraging health care providers
to engage patients in a process of shared decision making.
Conclusions
Many women who undergo first or second trimester
pre-natal screening are not using this information to in-
form their decision about amniocentesis. It is unclear if
this is a consequence of a quest for certitude associated
with a diagnostic procedure or if it is a failure of health
care providers to engage women in shared decision mak-
ing about pre-natal screening and amniocentesis. Future
research should illuminate the content of conversations
between women and health care providers to better assess
the quality of decision-making regarding amniocentesis.
While many women with low risk screening tests decide
to purse an amniocentesis that carries a risk of miscar-
riage, restricting public funding of amniocentesis to
women with advanced maternal age and high risk prenatal
screening is unlikely to dissuade women who want defini-
tive information on the status of their fetus from having
an amniocentesis. Offering women cell-free fetal DNA
testing may provide women with sufficient reassurance
such that they don’t feel compelled to have an amniocen-
tesis in the setting of low risk screening.
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